The Life Sciences team advised Nanobiotix S.A. in its definitive agreement under which Nanobiotix will grant Janssen Pharmaceutica NV an exclusive worldwide license (excluding People’s Republic of China, Macau, Hong Kong, Thailand, Taiwan, South Korea, and Singapore) for the development and commercialization of NBTXR3, a first-in class radioenhancer developed by Nanobiotix designed to destroy tumors through physical cell death when activated by radiotherapy.
Nanobiotix will receive an upfront payment of $30 million and is eligible to receive in-kind regulatory and development support valued at up to $30 million, double-digit royalties on net sales of NBTXR3, and success-based payments of up to $1.8 billion upon the achievement of certain development, regulatory, and sales milestones. Nanobiotix also is eligible to receive up to $30 million in equity investments from Johnson & Johnson Innovation – JJDC, Inc.
The transaction is pending completion of standard review under antitrust laws, including the Hart-Scott-Rodino Antitrust Improvements Act of 1976 in the United States.
Nanobiotix is a late-stage clinical biotechnology company pioneering disruptive, physics-based therapeutic approaches to revolutionize treatment outcomes for millions of patients; supported by people committed to making a difference for humanity. Nanobiotix’s philosophy is rooted in the concept of pushing past the boundaries of what is known to expand possibilities for human life.
Janssen is one of the Pharmaceutical Companies of Johnson & Johnson, working tirelessly to make disease a thing of the past for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. Janssen focuses on areas of medicine where they can make the biggest difference: Cardiovascular, Metabolism & Retina; Immunology; Infectious Diseases & Vaccines; Neuroscience; Oncology; and Pulmonary Hypertension.